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Factor VIII (FVIII), a plasma glycoprotein,is a crucial co-factor required by activatedfactor IX (FIXa) to activate factor X (FX) in
blood coagulation. Deficiency of this co-factor
results in the bleeding disorder hemophilia A
(OMIM #306700), a typical X-chromosome
linked recessive disorder that results in a
bleeding diathesis.1 Clinically, although the
severity of bleeding correlates well with resid-
ual FVIII coagulant activity (FVIII:C), pheno-
typic variation can be observed between
patients with identical FVIII:C levels or even
between patients with the same genetic
defect. However to date, F5 Leiden has been
the only consistently reported genetic throm-
botic risk factor to moderate the severity of
hemophilia A.2 With the exception of recur-
rent intron 22 (IVS22) and intron 1 (IVS1)
inversions (resulting in severe disease) and
frameshift mutations in the “6-9 consecutive
As” hotspot sequence motifs in exon 14, the
molecular basis of hemophilia A is character-
ized by a large number of heterogeneous fam-
ily-specific mutations. Based on the residual
circulating coagulant activity (FVIII:C) and
antigen (FVIII:Ag) level, hemophilia A patients
are classified into two main phenotypic
groups termed as cross-reacting material-neg-
ative (CRM ) and CRM-positive (CRM+), and
a subgroup of the latter denominated CRM-
reduced (CRMr).1 Generally, CRM– indicates
that disease is due to a lack of circulating FVIII
protein, while CRM+ results from normal cir-
culation of a dysfunctional protein. Within a
hemophiliac population there is an equilibri-
um between the elimination of life-threaten-
ing mutations and a constant input of de novo
alterations. Currently, hemophilia A is no
longer regarded as a life-threatening disorder:
therefore, elimination of mutations leading to
severe hemophilia A may be expected to slow
down. This may not be the case with certain
FVIII alterations leading to inhibitory antibody
formation, which is still a major life-threaten-
ing complication of hemophilia A. During the
last two decades a large number of F8 muta-
tions have been reported and these are sum-
marized in the HAMSTeRS F8 mutation data-
base (http://europium.csc.mrc.ac.uk/). Despite the
large number of laboratories reporting F8
genotypic data, identification of novel muta-
tions, as is the case here, continues to add sig-
nificant information regarding the structural-
functional, genotype-phenotype correlations
and contributes to a better understanding of
the molecular pathology of hemophilia A.
Design and Methods
Blood samples were obtained from hemo-
philia A patients of Portuguese origin and their
relatives following informed consent. FVIII:C
was measured by the one-stage clotting assay,
while FVIII:Ag was determined by ELISA
(ASSERACHROM, Diagnostica Stago,
Asnières, France). FVIII inhibitors were deter-
mined by the standard Bethesda method.
Genomic DNA was extracted with the
Wizard Genomic DNA Purification kit
(Promega, Madison, WI, USA). A total of 14
kb of the F8 gene, including the entire coding
sequence, exon-intron junctions and part of
the 5' and 3' untranslated regions, were ampli-
fied by polymerase chain reaction (PCR).
Most of the primers and amplification condi-
tions have been previously reported;3 primer
sequences, annealing temperatures and the
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size of PCR fragments are available on request. Single-
strand conformation polymorphism analysis (SSCP) was
performed essentially as described previously.3 Presently,
fragments are sequenced using the BigDye sequencing kit
(Applied Biosystems, Foster City, CA, USA) and reaction
products are separated on Applied Biosystems 377 PRISM
automated sequencer according to the manufacturer's
instructions. Screening for the F8 IVS22 inversion is
presently carried out by the long-distance sub-cycling-
PCR method4 while the recently reported F8 IVS1 inver-
sion was screened for by multiplex-PCR.5 Isolation of Poly
A+ RNA and reverse transcript RT-PCR was performed as
previously described.6
Whenever possible, family studies were performed in
all available relatives by two independent methodologies
(SSCP analysis, direct sequencing or restriction enzyme
cleavage). One hundred and fifty healthy unrelated male
individuals were used as controls. Haplotype analysis for
three intragenic F8 polymorphisms, the biallelic BclI with-
in IVS18 and the two dinucleotide repeats: IVS13-(CA)16-24
and IVS22-(GT)n(AG)n, of the F8 gene, was performed.
The families were also screened for the F5 Leiden muta-
tion (R506Q) by a multiplex PCR-SSCP. Molecular model-
ing was carried out using the five-domain FVIII model7
and the porcine FIXa model,8 using InsightII software
(Accelrys, Cambridge, UK) mounted on a Silicon Graphics
Indigo graphics workstation (Reading, UK).
Results and Discussion
F8 IVS22 and IVS1 inversions
Of 135 unrelated severe hemophilia A patients (47%
with sporadic hemophilia A), 73 (54%) had IVS22 inver-
sions and two (1.5%) had an IVS1 inversion. Sixteen per-
cent of the patients with an inversion developed inhibito-
ry antibodies against FVIII, thus supporting the conclusion
that F8 inversions are not a major predisposing factor for
this complication.
Missense and nonsense mutations
Forty-four different point (missense and nonsense)
mutations were identified in 70 Portuguese families and
are summarized in Supplementary Table 1 and Figure 1,
online version. Eighteen of these are novel mutations and
are discussed below. The C153F substitution reported
here confirms the expected CRM– status of alterations
involving this structurally important residue. Replacement
leads to disruption of a conserved disulphide bridge
(C153-C179) in the A1 domain.  The D163A substitution,
identified in a patient with moderate hemophilia A, lies at
the A1/A3 interface with H-bonds predicted to H2007.
Replacement with the smaller Ala sidechain can be toler-
ated in the models but with loss of interdomain H-bonds.
Although FVIII:Ag data from our patient are unavailable,
we predict a CRM– phenotype for this variant. K166 is a
core residue close to the A1/A3 interface, and replacement
with the Glu sidechain, in the K166E variant associated
with mild hemophilia A, is sterically difficult due to clash-
es with S170 and/or K206. In the absence of a FVIII:Ag
value we suggest this variant is likely to be CRM–. The
H281P substitution is an alteration identified in a patient
with severe hemophilia A. The His residue is conserved in
all FVIII and FV A1 domains, but not in A2, A3 or in CP:
in the homologous region A3 has a short insertion
sequence. H281 is placed at one end of the pseudo-three-
fold A1/A2/A3 axis at the A1/A2 interface and very close
to A3. A single H-bond is predicted from the His sidechain
to that of S524, forming another A1-A2 link adjacent to
that predicted for R282-D525, already implicated in the
stability of activated FVIII.9 Replacement with the Pro
sidechain can be sterically tolerated but the H-bond is lost.
The Y431C substitution is associated with moderate to
mild CRM– hemophilia A. The Tyr residue is conserved in
domain A2 of all species of FVIII, and related proteins FV
and CP. Replacement with Cys is sterically allowed but
illegitimate disulphide linkage is likely. This alteration, in
family F35, was found in association with the recently
reported polymorphic von Willebrand factor (vWF)
R924Q variant.10
The novel Y511C substitution, found in eight apparent-
ly unrelated families, is one of the most frequently identi-
fied missense mutations in Portuguese patients with mild
hemophilia A, having a clear CRM– phenotype. F8 haplo-
type analysis in these families indicates that this alteration
was introduced in the Portuguese population by an ances-
tral founder effect. Y511 is an A2 core residue, packed
closely by I463, F465, N474, I475, R484 and W513
(Supplementary Figure 2, online version). Replacement with
Cys likely gives rise to steric clashes with I463 or W513
and there is also the possibility of illegitimate disulphide
bond formation resulting in a low circulating FVIII:Ag
level, although the protein that does circulate appears
functionally normal.
The R698Q substitution leads to a phenotype similar to
that of two different variants of the same residue report-
ed in the database (FVIII:C/FVIII:Ag 44%/63%). R698 is
conserved in the A2 domains of all FVIII species at the
A2/A3 interface and mutation results in a mild functional
defect and enhanced A2 domain dissociation.11
The R1696P and D1769G substitutions can be treated
together since both affect residues which are predicted to
interact through a H-bond, holding together two beta-
strands on the surface of the A3 domain;9 each might
therefore lead to a similar hemophilia A phenotype.
R1696P was identified in a patient with moderate hemo-
philia A but no FVIII:Ag value is available, while D1769G
was identified in a moderately affected CRM– patient.
Replacement of R1696 with proline is predicted to abolish
the H-bond, and introduce a steric clash with D1769 lead-
ing to misfolding and intracellular retention or instability.
Variant A1701D was found in a patient with CRM– severe
hemophilia A. The A1701 sidechain lies in a small pocket
near the A3 domain surface, enclosed by six A3 residues.
The larger Asp sidechain cannot be accommodated due to
clashes with Q1736, F1743, R1776 or Q1778 predicted to
result in severe misfolding or poor stability of the FVIII
variant.
R1721M is an alteration that was found in a patient
with severe CRM– hemophilia A. R1721 is a FVIII A3-spe-
cific residue which probably lies in an accessible surface
loop close to the A1/A3 interface but distant from other
predicted interactions, and is reported to be a FXa cleav-
age site (Supplementary Figure 3, online version).12 The
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replacement Met sidechain can be sterically accommodat-
ed so no reason for a CRM– phenotype is apparent. This
substitution, affecting the last amino acid of exon 14, also
reduces the donor splice site consensus value (CV) from
0.83 to 0.70, most likely reducing F8 pre-mRNA process-
ing efficiency.
The D1740N alteration leads to moderate CRM+ hemo-
philia A with a dysfunctional FVIII variant circulating at
mildly reduced protein levels. D1740 lies in an A3 surface
loop on the FVIII model and the sidechain is likely to be
solvent-exposed. Replacement with Asp creates an N-gly-
cosylation signal (N-G-S) and it is therefore likely to be
glycosylated. On inspection of a model of the membrane-
bound FVIII/FIXa complex,7,8 we predict that the function-
al defect results from interference with the FVIII-FIXa
interaction on the membrane, since the glycosylated
N1740 residue lies close to the predicted position of FIXa
(Supplementary Figure 4, online version). H1755R was identi-
fied in a severely affected CRM– hemophilia A patient.
H1755 is completely conserved in the A3 domains of
FVIII, FV and CP but not in A1 or A2. The residue lies in
a cleft on the A3 surface distant from A1/A2 and FIXa but
fairly close to the predicted position of C1.7 Replacement
with the larger Arg sidechain appears sterically forbidden
due to clashes with L1752, E1754 and V1873.
The W2062C substitution in the C1 domain was iden-
tified in a patient with severe CRM– hemophilia A. In the
C1 homology model7 the large Trp sidechain is complete-
ly buried, packed by S2040, A2047, P2153, S2160, T2064
and S2069. The smaller Cys sidechain can hypothetically
be accommodated into the pocket, so the CRM– pheno-
type probably results from illegitimate disulphide bonding
leading to poor secretion or stability. We found two novel
CRM– substitutions in the C2 domain, Q2246K and
G2285R. Q2246 is buried near the surface of the C2
domain and distant from the putative phospholipid inter-
face, enclosed by L2210, H2211, F2290, P2292 and R2320
and H-bonded to main chain atoms. Replacement with
the larger Lys sidechain may lead to a steric clash but this
might be mitigated by local refolding in the region of
F2290. This mutation is associated with a moderate rather
than a severe secretion/stability defect.
G2285R is the third most frequent missense mutation in
the Portuguese population. This alteration was also intro-
duced by a founder effect. This residue is in a β-sheet
environment near the domain surface, distant from puta-
tive interactions with other domains or the phospholipid
interaction surface. The large Arg sidechain cannot be
accommodated leading to severe steric clashes with
T2245, V2257, K2258, P2260 and L2319, presumably
resulting in misfolding and a fairly severe secretion/stabil-
ity defect.
Eight nonsense mutations (novel K992X), were also
identified in patients with severe CRM– hemophilia A
patients (Supplementary Table 1, online version). R583X,
identified in a patient with sporadic hemophilia A, was
the only case in which somatic mosaicism was observed
in the patient's mother.
Insertions and deletions
Nineteen different insertions or deletions (14 of which
are novel) were identified in 28 hemophilia A families of
Portuguese origin (Supplementary Table 2, online version).
The model of slipped mispairing during DNA replication
can explain most of these insertions/deletions. The inser-
tion:deletion ratio in runs of consecutive 6-9 As in F8
exon 14, reported in the HAMSTeRS database (3:0 at
codons 961-963 and 1080-1081; 19:5 at codons 1439-
1441; and 12:33 at codons 1191-1194) suggests, in accor-
dance with our data, that shorter runs are more insertion-
prone while longer runs are more deletion-prone.
Unusually, three frameshift mutations were associated
with a phenotype of only moderate severity. In two fam-
ilies, F1207 and F2614, the 1-nt deletion in the A9
sequence was associated with moderate hemophilia
A.The third patient (F674) had an insertion in the A6
sequence at codons 961-964 and was also heterozygous
for the F5 Leiden mutation. The F5 Leiden mutation may
contribute to the moderate phenotype observed.
We report two novel in-frame 3-bp deletions (R1696del
and E1970del) predicting the removal of single amino
acids from the A3 domain of FVIII:C, both of which were
unusually associated with circulating protein. Modeling
in the vicinity of R1696 is tentative, however, this residue
is located on a surface strand which could be shortened
(Supplementary Figure 5, online version) suggesting that fold-
ing and secretion might be possible. The phenotype is
CRMr with an inhibitor, indicating defective secretion of
an inactive protein. The phenotype of E1970del indicates
a very mild defect in secretion of a functionally normal
protein. Recurrent prolonged bleeding after dental extrac-
tion was the only manifestation of the FVIII deficiency.
E1970 is conserved in FVIII A3, probably at the A1/A3
interface in a short tripeptide insertion loop in compari-
son with the A2 and A3 domains, which suggests that the
single residue could be deleted without significant struc-
tural consequences. 
A novel large deletion of 4044bp, including the intron
13/exon 14 acceptor splice site was also identified (F1853)
in a patient with CRM– severe hemophilia A.
Splice site mutations 
Four splice site mutations have also been identified
(Supplementary Table 3 and Figures 1 and 6, online version),
at IVS 6 and 11 donor splice sites (both novel) and IVS 4
and 24 acceptor splice sites. RT-PCR analysis of ectopi-
cally transcribed F8 mRNA of the patient with the IVS24-
1G→A splice site mutation (F2672) revealed skipping of
exon 25 alone or, in approximately 30% of the processed
F8 mRNA, of exons 19 and 25 (Supplementary Figure 6D),
predicting in-frame removal of the corresponding
polypeptides. Alternative splicing of exon 19 in ectopic
F8 mRNA has been reported in normal control samples
as well as in patients with undetected F8 mutations.13
The donor splice site mutation in IVS6 +1G→A results in
skipping of surrounding exons 4-7 (Supplementary Figure
6B, online version) while the IVS11+1G>A, results in exci-
sion of exons 10 and 11 (Supplementary Figure 6C, online
version).
Hemophilia A patients without an obvious causative F8
mutation 
No obvious disease-causing F8 mutation was found in
three hemophilia A patients (approximately 1.5% of the
D. David et al.
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patient group) even after sequencing of the known func-
tionally important F8 gene regions (Supplementary Table 4,
online version). This is in accordance with previously
reported data13,14 regarding the proportion of patients with
undetectable mutations in the F8 coding sequences. 
The variant V1982V in exon 19 (F2832; Supplementary
Table 4) was the only F8 mutation identified in two
daughters of a patient diagnosed with mild hemophilia A
(FVIII:C= 6%). This silent (T→C) mutation at position +5
of exon 19 was not identified in either the male control
group or in the group of hemophiliacs or relatives ana-
lyzed by SSCP. The CV of the IVS18 acceptor splice site
is one of the lowest observed in the F8 gene (0.72 vs. 0.87,
the mean of the CV of all acceptor splice sites in the F8
gene). A cryptic splice site is present at position +11 in
exon 19 with a CV of 0.73, and the apparently silent
mutation is located between these two sites. Taking
together these data we cannot assume or exclude that this
is a causative mutation. In this family the known von
Willebrand’s disease type 2N R816W substitution was
also identified in the heterozygous state (data not shown).
In this case, the identified vWF mutation alone is unlike-
ly to explain the reduced FVIII:C level of 6% observed in
the patient. Family 1377 included the only case of severe
hemophilia A in which a disease-causing FVIII mutation
was not identified.
Concluding remarks
In 177 of 181 families the relationship between the
identified mutation and the FVIII deficiency was clearly
demonstrated. Several missense mutations associated
with mild to moderate hemophilia A (Y511C, Q2189E
and G2285R) were introduced into the Portuguese popu-
lation by an ancestral founder effect, and presently repre-
sent the molecular basis of hemophilia A in a considerable
number of patients. These relatively frequent, popula-
tion-specific, missense mutations together with the de
novo alterations can lead to significant differences in the
spectrum of F8 mutations among different populations.
The analytical sensitivity of the SSCP screening method
in this study was near to 100%. 
The heterogeneity observed at the mutational level is
greatly simplified at phenotypic level. The large majority
of mutations are associated with CRM– hemophilia A,
mostly due to misfolding and secretion/stability defects.
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